In this context, an observational prospective study was conducted to evaluate the impact of BBs, angiotensin-converting enzyme inhibitors (ACEIs) and CCBs (amlodipine) on iron metabolism in patients with heart failure. This evidence concerns the gene ACE and heart failure.